BNTC
Benitec Biopharma Inc.
Biotechnology
Market Cap$416M
5Y Perf.-90.1%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
BNTC vs REGN vs NTLA vs BEAM
Revenue, margins, valuation, and 5-year total return — side by side.
REGN
Regeneron Pharmaceuticals, Inc.
Biotechnology
Market Cap$73.68B
5Y Perf.+16.7%
NTLA
Intellia Therapeutics, Inc.
Biotechnology
Market Cap$1.62B
5Y Perf.-19.5%
BEAM
Beam Therapeutics Inc.
Biotechnology
Market Cap$3.23B
5Y Perf.+26.5%
BNTC vs REGN vs NTLA vs BEAM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BNTC | REGN | NTLA | BEAM |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $416M | $73.68B | $1.62B | $3.23B |
| Revenue (TTM) | $556K | $14.92B | $68M | $132M |
| Net Income (TTM) | $-51M | $4.42B | $-413M | $-65M |
| Gross Margin | -1.2% | 84.5% | -25.6% | -64.2% |
| Operating Margin | -99.9% | 24.3% | -6.5% | -281.0% |
| Forward P/E | — | 15.3x | — | — |
| Total Debt | $849K | $2.71B | $93M | $294M |
| Cash & Equiv. | $98M | $3.12B | $155M | $295M |
BNTC vs REGN vs NTLA vs BEAM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BNTC
REGN
NTLA
BEAM
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Benitec Biopharma I… (BNTC) | 100 | 9.9 | -90.1% |
| Regeneron Pharmaceu… (REGN) | 100 | 116.7 | +16.7% |
| Intellia Therapeuti… (NTLA) | 100 | 80.5 | -19.5% |
| Beam Therapeutics I… (BEAM) | 100 | 126.5 | +26.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BNTC vs REGN vs NTLA vs BEAM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: REGN leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Beam Therapeutics Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
BNTC
Benitec Biopharma Inc.
The Defensive Pick
BNTC is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.35, Low D/E 0.9%, current ratio 54.67x
- Beta 1.35, current ratio 54.67x
Best for: sleep-well-at-night and defensive
REGN
Regeneron Pharmaceuticals, Inc.
The Income Pick
REGN carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 0.81, yield 0.5%
- 90.0% 10Y total return vs BEAM's 67.8%
- 29.6% margin vs BNTC's -91.5%
- Beta 0.81 vs NTLA's 2.37, lower leverage
Best for: income & stability and long-term compounding
NTLA
Intellia Therapeutics, Inc.
The Secondary Option
NTLA lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
BEAM
Beam Therapeutics Inc.
The Growth Play
BEAM is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 120.0%, EPS growth 82.3%, 3Y rev CAGR 31.9%
- 120.0% revenue growth vs BNTC's -141.6%
- +93.9% vs BNTC's -10.3%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BEAM | 120.0% revenue growth vs BNTC's -141.6% |
| Quality / Margins | REGN | 29.6% margin vs BNTC's -91.5% |
| Stability / Safety | REGN | Beta 0.81 vs NTLA's 2.37, lower leverage |
| Dividends | REGN | 0.5% yield; 1-year raise streak; the other 3 pay no meaningful dividend |
| Momentum (1Y) | BEAM | +93.9% vs BNTC's -10.3% |
| Efficiency (ROA) | REGN | 11.1% ROA vs NTLA's -45.2%, ROIC 8.9% vs -44.0% |
BNTC vs REGN vs NTLA vs BEAM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2023
FY 2025
Segment breakdown not available.
Segment breakdown not available.
BNTC vs REGN vs NTLA vs BEAM — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLREGNLAGGINGBEAM
Who Leads Where
REGN leads in 2 of 6 categories
BNTC leads 0 • NTLA leads 0 • BEAM leads 0 • 3 tied
Explore the data ↓BEAMBeam Therapeutics Inc.
0leads
NTLAIntellia Therapeutics…
0leads
BNTCBenitec Biopharma Inc.
0leads
REGNRegeneron Pharmaceuti…
2leads
6 Total Categories
CATEGORYLEADERvs BNTCvs NTLAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
REGN4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
REGN7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
REGN leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
REGN is the larger business by revenue, generating $14.9B annually — 26833.8x BNTC's $556,000. REGN is the more profitable business, keeping 29.6% of every revenue dollar as net income compared to BNTC's -91.5%. On growth, NTLA holds the edge at +78.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | BNTCBenitec Biopharma… | REGNRegeneron Pharmac… | NTLAIntellia Therapeu… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $556,000 | $14.9B | $68M | $132M |
| EBITDAEarnings before interest/tax | -$56M | $4.2B | -$431M | -$355M |
| Net IncomeAfter-tax profit | -$51M | $4.4B | -$413M | -$65M |
| Free Cash FlowCash after capex | -$19M | $4.2B | -$396M | -$384M |
| Gross MarginGross profit ÷ Revenue | -1.2% | +84.5% | -25.6% | -64.2% |
| Operating MarginEBIT ÷ Revenue | -99.9% | +24.3% | -6.5% | -2.8% |
| Net MarginNet income ÷ Revenue | -91.5% | +29.6% | -6.1% | -49.2% |
| FCF MarginFCF ÷ Revenue | -33.7% | +27.9% | -5.8% | -2.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +19.0% | +78.8% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +21.2% | -7.2% | +34.6% | +26.6% |
REGN leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — REGN and NTLA and BEAM each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | BNTCBenitec Biopharma… | REGNRegeneron Pharmac… | NTLAIntellia Therapeu… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| Market CapShares × price | $416M | $73.7B | $1.6B | $3.2B |
| Enterprise ValueMkt cap + debt − cash | $319M | $73.3B | $1.6B | $3.2B |
| Trailing P/EPrice ÷ TTM EPS | -11.56x | 17.09x | -3.60x | -38.85x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 15.35x | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | 2.70x | — | — |
| EV / EBITDAEnterprise value multiple | — | 17.78x | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 5.14x | 23.93x | 23.14x |
| Price / BookPrice ÷ Book value/share | 4.52x | 2.46x | 2.21x | 2.51x |
| Price / FCFMarket cap ÷ FCF | — | 18.06x | — | — |
Evenly matched — REGN and NTLA and BEAM each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
REGN leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
REGN delivers a 14.3% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-57 for NTLA. BNTC carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to BEAM's 0.24x. On the Piotroski fundamental quality scale (0–9), REGN scores 5/9 vs BNTC's 3/9, reflecting solid financial health.
| Metric | BNTCBenitec Biopharma… | REGNRegeneron Pharmac… | NTLAIntellia Therapeu… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -27.2% | +14.3% | -56.6% | -5.9% |
| ROA (TTM)Return on assets | -26.7% | +11.1% | -45.2% | -4.6% |
| ROICReturn on invested capital | — | +8.9% | -44.0% | -31.1% |
| ROCEReturn on capital employed | -57.6% | +10.2% | -48.5% | -33.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.01x | 0.09x | 0.14x | 0.24x |
| Net DebtTotal debt minus cash | -$97M | -$412M | -$62M | -$1M |
| Cash & Equiv.Liquid assets | $98M | $3.1B | $155M | $295M |
| Total DebtShort + long-term debt | $849,000 | $2.7B | $93M | $294M |
| Interest CoverageEBIT ÷ Interest expense | — | 108.44x | — | 1.08x |
REGN leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — BNTC and REGN each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in REGN five years ago would be worth $14,365 today (with dividends reinvested), compared to $1,692 for BNTC. Over the past 12 months, BEAM leads with a +93.9% total return vs BNTC's -10.3%. The 3-year compound annual growth rate (CAGR) favors BNTC at 48.1% vs NTLA's -31.8% — a key indicator of consistent wealth creation.
| Metric | BNTCBenitec Biopharma… | REGNRegeneron Pharmac… | NTLAIntellia Therapeu… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -3.5% | -8.5% | +48.9% | +16.0% |
| 1-Year ReturnPast 12 months | -10.3% | +27.1% | +88.1% | +93.9% |
| 3-Year ReturnCumulative with dividends | +224.6% | -5.1% | -68.3% | -5.6% |
| 5-Year ReturnCumulative with dividends | -83.1% | +43.6% | -79.8% | -55.6% |
| 10-Year ReturnCumulative with dividends | -97.0% | +90.0% | -42.9% | +67.8% |
| CAGR (3Y)Annualised 3-year return | +48.1% | -1.7% | -31.8% | -1.9% |
Evenly matched — BNTC and REGN each lead in 2 of 6 comparable metrics.
Risk & Volatility
Evenly matched — REGN and BEAM each lead in 1 of 2 comparable metrics.
Risk & Volatility
REGN is the less volatile stock with a 0.81 beta — it tends to amplify market swings less than NTLA's 2.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BEAM currently trades 86.4% from its 52-week high vs NTLA's 48.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BNTCBenitec Biopharma… | REGNRegeneron Pharmac… | NTLAIntellia Therapeu… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.31x | 0.77x | 2.21x | 2.08x |
| 52-Week HighHighest price in past year | $17.15 | $821.11 | $28.25 | $36.44 |
| 52-Week LowLowest price in past year | $9.93 | $476.49 | $6.83 | $15.35 |
| % of 52W HighCurrent price vs 52-week peak | +70.8% | +86.4% | +48.5% | +86.4% |
| RSI (14)Momentum oscillator 0–100 | 55.1 | 44.9 | 50.4 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 144K | 631K | 5.3M | 2.0M |
Evenly matched — REGN and BEAM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: BNTC as "Buy", REGN as "Buy", NTLA as "Buy", BEAM as "Buy". Consensus price targets imply 163.6% upside for BNTC (target: $32) vs 22.1% for REGN (target: $866). REGN is the only dividend payer here at 0.48% yield — a key consideration for income-focused portfolios.
| Metric | BNTCBenitec Biopharma… | REGNRegeneron Pharmac… | NTLAIntellia Therapeu… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $32.00 | $865.68 | $20.00 | $40.83 |
| # AnalystsCovering analysts | 7 | 48 | 39 | 27 |
| Dividend YieldAnnual dividend ÷ price | — | +0.5% | — | — |
| Dividend StreakConsecutive years of raises | — | 1 | — | — |
| Dividend / ShareAnnual DPS | — | $3.41 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +5.4% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
REGN leads in 2 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 3 categories are tied.
Best OverallRegeneron Pharmaceuticals, … (REGN)Leads 2 of 6 categories
Loading custom metrics...
BNTC vs REGN vs NTLA vs BEAM: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is BNTC or REGN or NTLA or BEAM a better buy right now?
For growth investors, Beam Therapeutics Inc.
(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 1x trailing P/E (15. 3x forward), making it the more compelling value choice. Analysts rate Benitec Biopharma Inc. (BNTC) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BNTC or REGN or NTLA or BEAM?
Over the past 5 years, Regeneron Pharmaceuticals, Inc.
(REGN) delivered a total return of +43. 6%, compared to -83. 1% for Benitec Biopharma Inc. (BNTC). Over 10 years, the gap is even starker: REGN returned +91. 6% versus BNTC's -97. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BNTC or REGN or NTLA or BEAM?
By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc.
(REGN) is the lower-risk stock at 0. 77β versus Intellia Therapeutics, Inc. 's 2. 21β — meaning NTLA is approximately 188% more volatile than REGN relative to the S&P 500. On balance sheet safety, Benitec Biopharma Inc. (BNTC) carries a lower debt/equity ratio of 1% versus 24% for Beam Therapeutics Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — BNTC or REGN or NTLA or BEAM?
By revenue growth (latest reported year), Beam Therapeutics Inc.
(BEAM) is pulling ahead at 120. 0% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Beam Therapeutics Inc. grew EPS 82. 3% year-over-year, compared to 8. 2% for Regeneron Pharmaceuticals, Inc.. Over a 3-year CAGR, BEAM leads at 31. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BNTC or REGN or NTLA or BEAM?
Regeneron Pharmaceuticals, Inc.
(REGN) is the more profitable company, earning 31. 4% net margin versus -91. 5% for Benitec Biopharma Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus -99. 9% for BNTC. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is BNTC or REGN or NTLA or BEAM more undervalued right now?
Analyst consensus price targets imply the most upside for BNTC: 163.
6% to $32. 00.
07Which pays a better dividend — BNTC or REGN or NTLA or BEAM?
In this comparison, REGN (0.
5% yield) pays a dividend. BNTC, NTLA, BEAM do not pay a meaningful dividend and should not be held primarily for income.
08Is BNTC or REGN or NTLA or BEAM better for a retirement portfolio?
For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc.
(REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 77)). Intellia Therapeutics, Inc. (NTLA) carries a higher beta of 2. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (REGN: +91. 6%, NTLA: -41. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between BNTC and REGN and NTLA and BEAM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BNTC is a small-cap quality compounder stock; REGN is a mid-cap deep-value stock; NTLA is a small-cap high-growth stock; BEAM is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.